GSK-2982772

N/A

Report date: 2024/06/17 20:00:40
NME

Base Information

Drug NameGSK-2982772
Drug Alias NameGSK-2982772
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor-interacting serine/threonine-protein kinase 1 inhibitors
TargetsReceptor-interacting serine/threonine-protein kinase 1
Therapy Area/IndicationsAutoimmune DiseasesPsoriasisInflammatory Bowel Diseases +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[11] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesN/A
Active IndicationsPsoriasis
Inactive IndicationsAutoimmune DiseasesInflammatory Bowel DiseasesColitis, Ulcerative +[4] 

Other Information

ATC CodeN/A
Related LinksN/A